Doxorubicin是一种有细胞毒性的蒽环类抗生素，常用作

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC₅₀ of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy^[1][2]. Doxorubicin inhibits human DNA topoisomerase I with an IC₅₀ of 0.8 μM^[3].

Combination of Doxorubicin (Hydroxydaunorubicin) and Simvastatin in the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin (Hydroxydaunorubicin) and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts^[5]. A single intraperitoneal injection 10 mg/kg (Doxorubicin 1) is administered in rats, 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, whereas Doxorubicin 2 and Doxorubicin 3 reached 80% mortality at days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3^[6].

543.52

C₂₇H₂₉NO₁₁

23214-92-8

阿霉素；多柔比星

• Quinones
• Anthraquinones

• Phenols
• Polyphenols

Streptomyces peucetius.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 1.

  Doxorubicin (dissolved with distilled water) is incorporated into 0.035% CaCl₂ solution^[5].

• 2.

  Doxorubicin (Adriamycin) is prepared in vehicle (PBS)^[6].

• [1]. Nitiss JL, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50. [Content Brief]

  [2]. Rhee HK, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8. [Content Brief]

  [3]. Foglesong PD, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5. [Content Brief]

  [4]. Sadeghi-Aliabadi H, et al. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci. 2010 Jul;5(2):127-33. [Content Brief]

  [5]. El-Zawahry A, et al. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancerxenografts. BMC Cancer. 2005 Jan 7;5:2. [Content Brief]

  [6]. Hayward R, et al. Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 2007 Jul;46(4):20-32. [Content Brief]

  [7]. Johansson S, et al. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS. 2006;20(15):1911-1915. [Content Brief]